ID954B - STEROID 3-SUBSTITUTED CARBOKSI-17β IS NOT SATURATED - Google Patents
STEROID 3-SUBSTITUTED CARBOKSI-17β IS NOT SATURATEDInfo
- Publication number
- ID954B ID954B IDP308292A ID923082A ID954B ID 954 B ID954 B ID 954B ID P308292 A IDP308292 A ID P308292A ID 923082 A ID923082 A ID 923082A ID 954 B ID954 B ID 954B
- Authority
- ID
- Indonesia
- Prior art keywords
- group
- chem
- hydrogen
- alkyl group
- cycloalkyl
- Prior art date
Links
- 229920006395 saturated elastomer Polymers 0.000 title 1
- 150000003431 steroids Chemical class 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 8
- 239000001257 hydrogen Substances 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 239000001301 oxygen Substances 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 150000002431 hydrogen Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000002911 monocyclic heterocycle group Chemical group 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 239000002677 5-alpha reductase inhibitor Substances 0.000 abstract 1
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 239000005864 Sulphur Chemical group 0.000 abstract 1
- 239000003098 androgen Substances 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0066—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by a carbon atom forming part of an amide group
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Dental Preparations (AREA)
- Details Of Garments (AREA)
- Ceramic Products (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention concerns steroidic 5 alpha -reductase inhibitors having the following formula (I) <CHEM> wherein Y is oxygen or sulphur; R is a group: a) -OR4, wherein R4 is hydrogen or a C1-C6 alkyl group; b) <CHEM> wherein each of R5 and R6, independently, is hydrogen or a C1-C6 alkyl group; c) <CHEM> wherein R7 is hydrogen or a C1-C6 alkyl group and W is a group: (i) <CHEM> wherein R8 is a C1-C6 alkyl group, a C5-C6 cycloalkyl group, a C6-C9 cycloalkylalkyl group, a phenyl group or a benzyl group; or (ii) <CHEM> wherein R9 is a C1-C6 alkyl group or a C5-C6 cycloalkyl group; or (iii) <CHEM> wherein R5 and R6 are as defined above; d) <CHEM> wherein each of R10 and R11 is, independently, hydrogen or a C1-C6 alkyl group or taken together with the nitrogen atom to which they are linked form a pentatomic or hexatomic saturated heteromonocyclic ring, optionally containing at least one additional heteroatom selected from oxygen and nitrogen, and n is an integer of 2 to 4; R1 is hydrogen, a C1-C6 alkyl group, a C5-C6 cycloalkyl group, a C6-C9 cycloalkyalkyl group or an aryl group; each of R2 and R3 is, independently, selected from the group consisting of hydrogen, C1-C6 alkyl, C5-C6 cycloalkyl, C6-C9 cycloalkylalkyl and aryl or R2 and R3, taken together with the nitrogen atom to which they are linked, form a pentatomic or hexatomic saturated heteromonocyclic ring, optionally containing at least one additional heteroatom selected from oxygen and nitrogen; and the symbol (----) represents a single or a double bond provided that when it is a double bond the hydrogen in the 5 alpha position doesn't exist and the pharmaceutically acceptable salts thereof. In view of their 5- alpha reductase inhibiting activity the compounds of the invention can be useful for the treatment of androgen dependent conditions.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI911432A IT1259419B (en) | 1991-05-24 | 1991-05-24 | 3-CARBOSE STEROIDS 17B - UNSATURATED SUBSTITUTES USEFUL AS INHIBITORS OF TESTOSTERONE 5 IN REDUCTASE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ID954B true ID954B (en) | 1996-09-25 |
Family
ID=11359980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IDP308292A ID954B (en) | 1991-05-24 | 1992-05-22 | STEROID 3-SUBSTITUTED CARBOKSI-17β IS NOT SATURATED |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US5212166A (en) |
| EP (2) | EP0540717B1 (en) |
| JP (1) | JP3226919B2 (en) |
| CN (1) | CN1035055C (en) |
| AT (1) | ATE155792T1 (en) |
| AU (1) | AU655280B2 (en) |
| CA (1) | CA2087953A1 (en) |
| CZ (1) | CZ281309B6 (en) |
| DE (1) | DE69221074T2 (en) |
| DK (1) | DK0540717T3 (en) |
| ES (1) | ES2106185T3 (en) |
| FI (1) | FI930277A7 (en) |
| HU (1) | HUT64083A (en) |
| ID (1) | ID954B (en) |
| IE (1) | IE921634A1 (en) |
| IL (1) | IL101947A (en) |
| IT (1) | IT1259419B (en) |
| MX (1) | MX9202438A (en) |
| MY (1) | MY131089A (en) |
| NO (1) | NO930244L (en) |
| NZ (1) | NZ242850A (en) |
| RU (1) | RU2104283C1 (en) |
| TW (1) | TW213467B (en) |
| WO (1) | WO1992020700A1 (en) |
| YU (1) | YU52992A (en) |
| ZA (1) | ZA923758B (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5618806A (en) * | 1992-04-30 | 1997-04-08 | Smithkline Beecham Corporation | 17α and 17β-substituted estra-1,3,5(10)-triene-3-carbboxlic acid |
| US5683995A (en) * | 1992-11-18 | 1997-11-04 | Smithkline Beecham Corporation | 17 substituted acyl-3-carboxy 3,5-diene steroidals as α-reductase inhibitors |
| US5641765A (en) * | 1992-11-18 | 1997-06-24 | Smithkline Beecham Corporation | 17-αand 17-βsubstituted acyl-3-carboxy-3,5-dienes and use in inhibiting 5-α-reductase |
| EP0717618B1 (en) * | 1993-09-03 | 2002-11-06 | Smithkline Beecham Corporation | Stabilized tablet formulation |
| GB9324371D0 (en) * | 1993-11-26 | 1994-01-12 | Erba Carlo Spa | Side chain fluoro substituted 3-carboxysteroids |
| US5430157A (en) * | 1993-12-13 | 1995-07-04 | Eli Lilly And Company | Reduced phenanthrenes |
| GB9402041D0 (en) * | 1994-02-03 | 1994-03-30 | Smithkline Beecham Corp | Compounds |
| US5714480A (en) * | 1994-03-31 | 1998-02-03 | Smithkline Beecham Corporation | Treating cardiovascular disease with steroidal 5-alpha-reductase inhibitors |
| WO1995028413A1 (en) * | 1994-04-15 | 1995-10-26 | Smithkline Beecham Corporation | 17β-SUBSTITUTED 3-CARBOXY STEROIDS THAT INHIBIT 5-α-REDUCTASE |
| GB9415183D0 (en) * | 1994-07-28 | 1994-09-21 | Erba Carlo Spa | 3-carboxysteroids with a fluorinated side-chain |
| US5543417A (en) * | 1994-10-21 | 1996-08-06 | Merck & Co., Inc. | Combination method of treating acne using 4-AZA-5α-cholestan-ones and 4-AZA-5α-androstan-ones as selective 5α-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents |
| ATE473759T1 (en) | 1998-05-22 | 2010-07-15 | Univ Leland Stanford Junior | BIFUNCTIONAL MOLECULES AND THERAPIES BASED THERAPIES. |
| HUP0203045A3 (en) * | 1999-09-22 | 2004-06-28 | Sanofi Aventis Deutschland | 4-benzylaminoquinoline conjugates with bile acid and their heteroanalogues, methods for producing the same, medicaments containing these compounds and their use |
| EP2392258B1 (en) | 2005-04-28 | 2014-10-08 | Proteus Digital Health, Inc. | Pharma-informatics system |
| US9062126B2 (en) | 2005-09-16 | 2015-06-23 | Raptor Pharmaceuticals Inc. | Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof |
| PL3395372T3 (en) | 2009-02-20 | 2022-07-25 | EnhanX Biopharm Inc. | Glutathione-based drug delivery system |
| CN102458374A (en) | 2009-05-06 | 2012-05-16 | 实验室护肤股份有限公司 | Skin delivery compositions comprising active agent-calcium phosphate particle complexes and methods of use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4377584A (en) * | 1978-04-13 | 1983-03-22 | Merck & Co., Inc. | 4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors |
| US5041433A (en) * | 1987-04-29 | 1991-08-20 | Smithkline Beecham Corporation | 11-keto or hydroxy 3,5-diene steroids as inhibitors of steriod 5-α-reductase |
| US4910226A (en) * | 1987-04-29 | 1990-03-20 | Smithkline Beckman Corporation | Steroid 5-alpha-reductase inhibitors |
| US5032586A (en) * | 1989-08-24 | 1991-07-16 | Smithkline Beecham Corporation | 7-keto or hydroxy 3,5-diene steroids as inhibitors of steroid 5-alpha reductase |
| US5091380A (en) * | 1990-06-28 | 1992-02-25 | Merck & Co., Inc. | N-monosubstituted adamantyl/norbornanyl 17β-carbamides of 3-carboxy-androst-3,5-dienes as testosterone 5α-reductase inhibitors |
| DK0567271T3 (en) * | 1992-04-20 | 1998-02-16 | Sankyo Co | Steroid derivatives for the treatment of prostate hypertrophy, method of preparation thereof and applications thereof |
-
1991
- 1991-05-24 IT ITMI911432A patent/IT1259419B/en active IP Right Grant
-
1992
- 1992-05-20 MY MYPI92000863A patent/MY131089A/en unknown
- 1992-05-20 YU YU52992A patent/YU52992A/en unknown
- 1992-05-21 IL IL10194792A patent/IL101947A/en active IP Right Grant
- 1992-05-21 NZ NZ242850A patent/NZ242850A/en unknown
- 1992-05-21 US US07/886,574 patent/US5212166A/en not_active Expired - Lifetime
- 1992-05-22 DE DE69221074T patent/DE69221074T2/en not_active Expired - Fee Related
- 1992-05-22 EP EP92910992A patent/EP0540717B1/en not_active Expired - Lifetime
- 1992-05-22 HU HU9300176A patent/HUT64083A/en unknown
- 1992-05-22 JP JP50978992A patent/JP3226919B2/en not_active Expired - Fee Related
- 1992-05-22 ID IDP308292A patent/ID954B/en unknown
- 1992-05-22 EP EP92108670A patent/EP0517047A1/en active Pending
- 1992-05-22 CZ CZ93265A patent/CZ281309B6/en unknown
- 1992-05-22 WO PCT/EP1992/001153 patent/WO1992020700A1/en not_active Ceased
- 1992-05-22 ES ES92910992T patent/ES2106185T3/en not_active Expired - Lifetime
- 1992-05-22 MX MX9202438A patent/MX9202438A/en unknown
- 1992-05-22 TW TW081104019A patent/TW213467B/zh active
- 1992-05-22 DK DK92910992.4T patent/DK0540717T3/en active
- 1992-05-22 ZA ZA923758A patent/ZA923758B/en unknown
- 1992-05-22 CA CA002087953A patent/CA2087953A1/en not_active Abandoned
- 1992-05-22 AT AT92910992T patent/ATE155792T1/en active
- 1992-05-22 RU RU93004939A patent/RU2104283C1/en active
- 1992-05-22 AU AU17781/92A patent/AU655280B2/en not_active Ceased
- 1992-05-23 CN CN92103919A patent/CN1035055C/en not_active Expired - Fee Related
- 1992-07-01 IE IE163492A patent/IE921634A1/en unknown
-
1993
- 1993-01-25 NO NO93930244A patent/NO930244L/en unknown
- 1993-05-22 FI FI930277A patent/FI930277A7/en not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ID954B (en) | STEROID 3-SUBSTITUTED CARBOKSI-17β IS NOT SATURATED | |
| FI865037A7 (en) | MICROBICIDAL COMPOSITION. | |
| HUP0302468A2 (en) | Alpha v integrin receptor antagonists and pharmaceutical compositions containing them | |
| HUP0004845A2 (en) | Substituted 4-hydroxy-phenylalcanoic acid derivatives with agonist activity to ppar-gamma and pharmaceutical compositions containing them | |
| CA2423103A1 (en) | N-acylsulfonamide apoptosis promoters | |
| DE68914292D1 (en) | Composition for the treatment of ischemic disorders in organs. | |
| KR920014810A (en) | Antibacterial agents | |
| MY101849A (en) | Improvements in or relating to cyanopyrazole herbicides. | |
| CO4910142A1 (en) | FURANO NITRONA COMPOUNDS | |
| ES2053764T3 (en) | ANTIPARASITIC AGENTS. | |
| BG60285B2 (en) | Method and herbicide for unwanted vegetation control | |
| HUT75647A (en) | Imidazolidinone derivatives and pharmaceutical compositions containing them, which are suitable for treament of senile dementia | |
| EP0798298A4 (en) | THIAZOLIDINONE COMPOUNDS OR MEDICINES OR PREVENTATIVES FOR TREATING ANGINA PECTORIS THAT CONTAINS IT AS ACTIVE INGREDIENTS | |
| DK0832079T3 (en) | Anti-ischemic hydroxylamine derivatives and pharmaceutical compositions | |
| NZ512803A (en) | Cyclic guanidine derivatives useful as pesticides | |
| BG46157A3 (en) | METHOD FOR PREPARATION OF N-ALKYL(EN)-N-(O,O-DI- SUBSTITUTED THIOPHOSPHORYL- N', N' - DI- SUBSTITUTED GLYCINAMIDES |